DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Rontalizumab
Rontalizumab
Review Article Biological Therapy in Systemic Lupus Erythematosus
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
New Treatments for Systemic Lupus Erythematosus on the Horizon: Targeting Plasmacytoid Dendritic Cells to Inhibit Cytokine Production Laura M
WO 2018/027204 Al 08 February 2018 (08.02.2018) W !P O PCT
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Type 1 Interferons in SLE Rontalizumab [Anti-Interferon-Α] the Interferon Signature Metric (ISM) Baseline ISM Status Defines 2
(INN) for Biological and Biotechnological Substances
Association of Endogenous Antiinterferon Autoantibodies with Decreased Interferonpathway and Disease Activity in Patients with S
Roche Group Development Pipeline
United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
A Phase 1B Clinical Trial Evaluating Sifalimumab, an Anti-IFN-Α
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
(12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
(INN) for Biological and Biotechnological Substances
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
Top View
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: an Overview
Assessment of the Evolution of Cancer Treatment Therapies
Unintended Immunological Consequences of Biologic Therapy
Therapeutic Focus – Roche and Astrazeneca Take Interferon Approach to Lupus
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
1 Reduction of Anterior Uveitis Flares in Patients with Axial
Trial of Anifrolumab in Active Systemic Lupus Erythematosus E.F
Biologic Therapies in Patients with Neuropsychiatric Systemic Lupus
Interferon Lambda in Inflammation and Autoimmune Rheumatic Diseases
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
A Promising Approach to Targeting Type 1 IFN in Systemic Lupus Erythematosus
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances 2009
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Autoantibody and Cytokine Profiles During Treatment with Belimumab
(INN) for Biological and Biotechnological Substances
Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate-To-Severe Systemic Lu
Safety, Tolerability and Pharmacokinetics of Subcutaneous and Intravenous Anifrolumab in Healthy Volunteers
Download Curriculum Vitae
Assessment of the Evolution of Cancer Treatment Therapies
WO 2015/036956 Al 19 March 2015 (19.03.2015) P O P C T
L 2018 Conference Needs Assessment
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri